An oral presentation will focus on the induction of autophagy by
Tumor Treating Fields
In total, 60 abstracts on Tumor Treating Fields, including two oral
presentations, will be presented
The volume of Tumor Treating Fields presentations marks a record
number of abstracts for Novocure at this conference
ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ:NVCR) announced today 13 preclinical presentations
highlighting data on Tumor Treating Fields’ mechanism of action at the
22nd Annual Meeting of the Society for Neuro-Oncology (SNO), November 16
through November 19, in San Francisco. These 13 preclinical
presentations add to the six clinical data presentations to be shared at
SNO this year. In total, 60 abstracts on Tumor Treating Fields,
including two oral presentations, will be presented. The volume of Tumor
Treating Fields presentations marks a record number of abstracts for
Novocure at this conference and demonstrates what we believe to be a
growing interest in Novocure’s cancer treatment among researchers and
clinicians throughout the world.
The 13 presentations include an oral presentation by Dr. Moshe Giladi,
Novocure’s Director of Preclinical Research, focusing on the induction
of autophagy by Tumor Treating Fields. Autophagy is a fundamental
process for degrading and recycling cellular components and is used by
tumor cells as a survival mechanism. The presentation concludes that
inhibition of autophagy using certain commercially available drugs
potentiated the efficacy of Tumor Treating Fields in preclinical tumor
models. Additional presentations discuss, among other topics, the
potential synergistic effect between Tumor Treating Fields and
immunotherapy or radiation therapy.
“Treatment with Tumor Treating Fields is broadly applicable and has
consistently shown an antimitotic effect in our preclinical and clinical
research to date,” Dr. Giladi said. “Novocure is committed to evolving
our understanding of Tumor Treating Fields’ mechanism of action and
potential clinical utility through the presentation of important
preclinical data.”
Oral presentation
(CBIO-16) Induction of autophagy following TTFields application serves
as a survival mechanism mediated by AMPK activation. A. Shteingauz. 2:55
– 3 p.m. PST Friday, November 17. (Location: 5A Metabolomics/Cell
Biology/Cell Signaling)
Poster presentations
(EXTH-45) The combination of TTFields and ABT-414 demonstrate superior
efficacy against glioma cells. R. Schneiderman. 7:30 to 9:30 p.m. PST
Friday, November 17. (Location: Golden Gate ballroom, B2 level)
(CBIO-30) Tumor treating fields (TTFields) inhibit cancer cell migration
and invasion by inducing reorganizing of the actin cytoskeleton and
formation of cell adhesions. R. Schneiderman. 7:30 to 9:30 p.m. PST
Friday, November 17. (Location: Golden Gate ballroom, B2 level)
(QLIF-20) Skin care products compatible with Tumor Treating Fields. M.
Lacouture. 7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden
Gate ballroom, B2 level)
(EXTH-66) Glioblastoma cells from a patient post-Tumor Treating Fields
(TTFields) therapy are sensitive to TTFields in vitro. S. Michelhaugh.
7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate
ballroom, B2 level)
(CSIG-01) Tumor Treatment Fields downregulate specific transcription
factors leading to reduced DNA repair capacity, increased replication
stress, the inhibition of mitophagy and enhanced cell death. M. Story.
7:30 to 9:30 p.m. PST Friday, November 17. (Location: Golden Gate
ballroom, B2 level)
(EXTH-19) Combination of in vitro Tumor Treating Fields and temozolomide
decrease proliferation in patient-derived glioblastoma cell lines. S.
Michelhaugh. 7:30 to 9:30 p.m. PST Friday, November 17. (Location:
Golden Gate ballroom, B2 level)
(RBIO-07) Tumor Treating Fields (TTFields) Delay DNA Damage Repair
Following Radiation Treatment of Glioma Cells: Implications for
Irradiation through TTFields Transducer Arrays. M. Giladi. 5 to 7 p.m.
PST Saturday, November 18. (Location: Golden Gate ballroom, B2 level)
(IMMU-59) Alternating electric fields (TTFields) induce immunogenic cell
death resulting in enhanced antitumor efficacy when combined with
anti-PD-1 therapy. T. Voloshin. 5 to 7 p.m. PST Saturday, November 18.
(Location: Golden Gate ballroom, B2 level)
(IMMU-48) Evaluating the in-vitro effects of Tumor Treating Fields on
T-cell responses. G. Diamant. 5 to 7 p.m. PST Saturday, November 18.
(Location: Golden Gate ballroom, B2 level)
(PDTM-26) Tumor treating fields (TTFields) have anti-proliferative
effects on pediatric brain tumor cell lines at clinically deliverable
field settings. S. Smith. 5 to 7 p.m. PST Saturday, November 18.
(Location: Golden Gate ballroom, B2 level)
(DDIS-15) Synergistic Inhibition of Glioma Cell Proliferation by
Withaferin A and Tumor Treating Fields. E. Chang. 5 to 7 p.m. PST
Saturday, November 18. (Location: Golden Gate ballroom, B2 level)
(TMIC-38) Modulation of cancer cell metabolism and immune phenotype by
TTFields. E. Wong. 5 to 7 p.m. PST Saturday, November 18. (Location:
Golden Gate ballroom, B2 level)
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called TTFields, the use of
electric fields tuned to specific frequencies to disrupt solid tumor
cancer cell division. Novocure’s commercialized product, Optune, is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating TTFields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania and New York City. Additionally, the
company has offices in Germany, Switzerland, Japan and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 23, 2017, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005521/en/
Source: Novocure